Sutro Biopharma to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Sutro Biopharma (NASDAQ: STRO), a company specializing in antibody drug conjugates (ADCs) for oncology, has announced its participation in two upcoming investor conferences. The company will present at The Citizens Life Sciences Conference in New York from May 7-8, 2025, and the BofA Securities 2025 Health Care Conference in Las Vegas from May 13-15, 2025. Webcasts of both presentations will be available on Sutro's website investor relations section, with replays accessible for at least 30 days after each event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, STRO gained 2.80%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in two upcoming investor conferences.
Conference Details:
The Citizens Life Sciences Conference
Date: May 7-8, 2025
Location: New York, NY
BofA Securities 2025 Health Care Conference
Date: May 13-15, 2025
Location: Las Vegas, NV
Webcasts of the presentations will be accessible through the News & Events page of the Investor Relations section of the Company’s website at www.sutrobio.com. Archived replays will be available for at least 30 days after the event.
About Sutro Biopharma
Sutro Biopharma, Inc., is relentlessly focused on the discovery and development of precisely designed cancer therapeutics to transform what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro is advancing a robust early-stage pipeline of novel exatecan and dual-payload antibody drug conjugates (ADCs), coupled with high-value collaborations and industry partnerships, which validate its continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.
Investor Contact
Emily White
Sutro Biopharma
(650) 823-7681
ewhite@sutrobio.com
Media Contact
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com